CDK2 Molecular Glues for Targeted Protein Degradation in Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutics that effectively mediate the degradation of specific proteins, such as cyclin-dependent kinase 2 (CDK2), for the treatment of diseases, particularly cancer.
Innovation Solution
Development of compounds that modulate cereblon to induce the targeted degradation of CDK2 by binding to both the E3 ligase and the target protein, promoting ubiquitination and subsequent proteasomal degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If molecular glues are used to mediate protein degradation, then targeted degradation of pathogenic proteins is achieved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent employs molecular glues as intermediary compounds that bind to both the E3 ligase (cereblon) and the target protein (CDK2), facilitating their interaction and enabling targeted degradation. This intermediary approach resolves the contradiction by providing a reliable degradation mechanism while maintaining manageable therapeutic complexity through a small molecule mediator rather than complex biologics
Solution Approach 2:
The patent utilizes small molecule compounds that induce conformational changes and alter the binding parameters of the E3 ligase-substrate interface. By changing the physical-chemical parameters of the protein-protein interaction through small molecule binding, the patent achieves reliable targeted degradation with relatively simple therapeutic agents
2Reliability
If small molecule degraders are used to treat cancer, then therapeutic effectiveness against tumors is improved, but the specificity of protein targeting becomes more challenging
Solution Approach 1:
The molecular glue acts as a specificity-determining intermediary that recognizes both the E3 ligase and the target protein through distinct binding interfaces. This dual recognition capability ensures high targeting specificity for CDK2 while maintaining broad cancer treatment effectiveness across solid and liquid tumors
Solution Approach 2:
The small molecule degrader exhibits local quality by having different binding regions that specifically interact with distinct sites on the E3 ligase and target protein. This localized specific binding ensures precise protein targeting while the overall molecular structure provides the therapeutic effectiveness needed for cancer treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively degrade CDK2, providing a therapeutic approach for treating various cancers, including solid and liquid tumors, by administering a therapeutically effective amount to subjects in need.
Implementation Method 1
The molecular glues bind to both the E3 ligase and the target protein, thereby mediating an alteration of the ligase surface and enabling an interaction with the target protein
Implementation Method 2
Promoting the targeted degradation of pathogenic proteins using small molecule degraders is emerging as a new modality in the treatment of diseases
Data Source
AI summary
Described herein, in part, are compounds that mediate the degradation of cyclin-dependent kinase 2 (CDK2), and are therefore useful in the treatment of various disorders, such as cancer.